Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer

worldpharmanewsDecember 10, 2018

Tag: FDA , Roche , Tecentriq , lung cancer

PharmaSources Customer Service